Chemotherapy before surgery for advanced colon cancer with high CEA
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial compares two approaches for local advanced colon cancer: giving chemotherapy (CAPEOX) before surgery versus going straight to surgery. It's for people with a high CEA level, a certain type of colon cancer, and no cancer spread.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 70 years old.
- You have colon cancer that is not MSI-H/dMMR type.
- Your cancer is at a high-risk stage (stage II with certain features or stage III) and has not spread to other organs.
- Your CEA level is above 5 ng/mL before starting treatment.
- You are well enough to have surgery (ECOG score 0-1) and will need to provide blood and tumor samples for testing.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests immunotherapy plus chemotherapy given before surgery for colon cancer that hasn’t spread. It aims to shrink or control the tumor and improve outcomes in people whose tumor has certain immune/biologic features.
This trial tests whether giving chemotherapy before surgery can improve outcomes for people with colon cancer that has grown into nearby tissue or lymph nodes but hasn't spread to other organs. It is for patients whose tumors are mismatch repair proficient (pMMR) or microsatellite stable (MSS).
This trial tests whether adding a new immunotherapy drug (ivonescimab) to standard chemotherapy (CAPOX) before surgery can improve outcomes for people with locally advanced colon cancer. It compares the combination to chemotherapy alone.
This Phase 2 trial studies giving chemotherapy plus immune therapy before surgery for certain colon cancers that do not have mismatch repair defects (MSS/pMMR). The goal is to shrink and control the tumor and improve outcomes compared with standard approaches.
This trial compares giving chemotherapy before surgery versus going straight to surgery for certain stage II/III colon cancers. It may help shrink the tumor and improve outcomes by testing which approach works best for high-risk cases.
This trial tests a combination of three chemotherapy drugs (nanoliposomal irinotecan, oxaliplatin, and capecitabine) given before surgery to shrink locally advanced colorectal cancer that cannot be treated with radiation. The goal is to make the tumor removable with a better chance of complete removal (R0 resection).
Hear when a new Minimal Residual Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.